Compare Monster Beverage Corp (MNST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Recursion Pharmaceuticals Inc — how do they compare? Monster Beverage Corp trades at $43.6 (market cap $84.00B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Monster Beverage Corp is far larger — about 36.4× Recursion Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MNST | RXRX | |
|---|---|---|
Market Cap | $84.00B | $2.31B |
Volume | 8,371,981 | 40,478,768 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $6.79 |
52-Week Low | $33.16 | $2.84 |
Typical Hold Time | 72 Days | 22 Days |
Enterprise Value | $82.30B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net income margin of 23.08%. Recent news highlights its debt-free balance sheet and international expansion, particularly a 35% surge in overseas sales.
The outlook is mixed: strong fundamentals and analyst consensus support upside to a $98.22 price target, but the stock faces headwinds from rich valuations (P/E 39.7) and technical bearishness. Key risks include inflation pressures and regulatory challenges, such as India's label ban. Institutional sentiment leans bullish, with 52% of analysts rating it Buy.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
